Biotech Values

[DewDiligence]

PSDV:

So the drug doesn't work and it essentially gives you glaucoma!?!

The device does work to a degree; however, one of the two phase-3 trials clearly failed its primary endpoint and I think the second trial failed also if the p-value threshold is properly adjusted for the use of two doses.

Moreover, I think the company is deliberately delaying its CC until after the market close today in the hope that the bad news will get lost amid the holiday celebration.

If I were able to borrow shares, I would short this one aggressively.